A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 30, 2018

Study Completion Date

June 4, 2019

Conditions

Advanced Cancer

Interventions

BIOLOGICAL

CDX-0158 (formerly known as KTN-0158)

Single agent CDX-0158 until unacceptable toxicity or progressive disease

Trial Locations (4)

Sarah Cannon Research Institute, Nashville

Oregon Health & Sciences University, Portland

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston